Panobinostat + Cytarabine + Panobinostat
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoblastic Leukemia, Acute, Childhood
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Trial Timeline
Mar 1, 2011 → —
NCT ID
NCT01321346About Panobinostat + Cytarabine + Panobinostat
Panobinostat + Cytarabine + Panobinostat is a phase 1 stage product being developed by Novartis for Lymphoblastic Leukemia, Acute, Childhood. The current trial status is completed. This product is registered under clinical trial identifier NCT01321346. Target conditions include Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood, Hodgkin's Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01321346 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoblastic Leukemia, Acute, Childhood